However, results from both UKALLXII/E2993 B-ALL cohort and a single Japanese center showed favorable outcomes in TCF3-PBX1-positive patients, even more favorable than ZNF384 fusion [28, 29]. This evidence concerns the gene ZNF384 and precursor B-cell acute lymphoblastic leukemia.